3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors

The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and comp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: KELLUM, ALEX ANDREW, BLANCHE, SYDNEY TAYLOR, REN, LI, DOERNER BARBOUR, PATRICK MICHAEL, MORENO, DAVID AUSTIN, DAHLKE, JOSHUA RYAN, WITKOS, FAITH ELIZABETH, BLAKE, JAMES FRANCIS, CLARK, WESLEY DEWITT, COWDREY, CONNOR JAMES, KNAPP, ELLEN MARGARET, O'LEARY, JACOB MATTHEW, BOYS, MARK LAURENCE, ALLEN, SHELLEY
Format: Patent
Sprache:chi ; eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof. The invention further relates to solid forms of 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.